Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth

Sigma Pharmaceuticals (Australia) Pty Ltd and Generic Health Pty Ltd (collectively referred to as "the applicants") sought to have the patent held by Wyeth, which covers a method of administering venlafaxine hydrochloride, revoked. The applicants also sought a declaration that they had not infringed the patent and an injunction preventing Wyeth from enforcing the patent against them. Wyeth, in turn, claimed that the applicants had infringed the patent and sought an injunction preventing the applicants from continuing to infringe, as well as damages and an account of profits.

The primary legal issues before the court were whether the patent claims were valid, clear, and sufficiently described, and whether the applicants had infringed the patent. The court also needed to determine if the patent was obtained by false suggestion or misrepresentation and if the claimed invention was useful. The applicants argued that the patent was invalid on several grounds, including lack of inventive step, obviousness, and insufficiency of description. They also claimed that the patent was obtained by false suggestion or misrepresentation and that the invention was not useful. Wyeth argued that the patent was valid and that the applicants had infringed it.

The court found that the patent was valid, clear, and sufficiently described. The claims were not obvious and the invention was sufficiently described in the specification. The court rejected the applicants' argument that the patent was obtained by false suggestion or misrepresentation and found that the invention was useful. The court also found that the applicants had infringed the patent by marketing their products, which fell within the scope of the claims. The court dismissed the applicants' application for revocation of the patent and granted Wyeth's claims for infringement, injunctions, damages, and an account of profits.

The court ordered that the applicants be restrained from infringing the patent by importing, marketing, selling, or supplying the disputed products in Australia during the term of the patent without Wyeth's license or authority. The applicants were also ordered to destroy any infringing products in their possession and to pay Wyeth's costs of the proceeding. The court stayed certain orders pending any potential appeal to the Full Court of the Federal Court.